Overview

A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors

Status:
Not yet recruiting
Trial end date:
2025-10-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with Hemophilia B with inhibitors, as part of the SerpinPC registrational program.
Phase:
Phase 2
Details
Lead Sponsor:
ApcinteX Ltd
Collaborator:
Centessa Pharmaceuticals plc
Treatments:
Protein C